MIRA Pharmaceuticals, Inc. Reports Positive Proof-of-Concept Results for Oral SKNY-1 in Obese Mice

MIRA Pharmaceuticals reported initial positive proof-of-concept results for SKNY-1, its investigational oral candidate for obesity and metabolic disorders. The findings came from an exploratory pilot study in a diet-induced obesity mouse model; the provided article text ends before further results or numerical data.